Inventor · disambiguated record
Marna Williams
Also filed as: WILLIAMS MARNA · WILLIAMS MARNA B · WILLIAMS MARNA BROMBERG
11 granted patents·13 pending applications·160 citations·filing 2004–2022
92Inventor score
Files withGENENTECH INC10WILLIAMS MARNA6ABBVIE BIOTHERAPEUTICS INC3ABBOTT BIOTHERAPEUTICS CORP2FACET BIOTECH CORP1
Top patents by PatentIndex Score
24 records- 0197US8008450B2Therapeutic use of anti-CS1 antibodiesABBOTT BIOTHERAPEUTICS CORP·Filed 2009·Granted Aug 30, 2011·64 cites·4 claims
- 0293US7709610B2Therapeutic use of anti-CS1 antibodiesFACET BIOTECH CORP·Filed 2004·Granted May 4, 2010·40 cites·26 claims
- 0390US8461306B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted Jun 11, 2013·10 cites·19 claims
- 0488US8445646B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 21, 2013·8 cites·16 claims
- 0588US8444980B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 21, 2013·8 cites·40 claims
- 0688US8349330B2Therapeutic use of anti-CS1 antibodiesABBOTT BIOTHERAPEUTICS CORP·Filed 2011·Granted Jan 8, 2013·8 cites·16 claims
- 0788US8088898B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2009·Granted Jan 3, 2012·7 cites·9 claims
- 0887US8436146B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 7, 2013·7 cites·18 claims
- 0987US8133981B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2009·Granted Mar 13, 2012·6 cites·16 claims
- 1079US9175081B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 3, 2015·2 cites·36 claims
- 1178US2022349903A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2021·Application pending·0 cites
- 1271US2022357343A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2021·Application pending·0 cites
- 1369US2020031929A1Therapeutic use of anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1466US2010255508A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGELZLEICHTER THOMAS RICHARD·Filed 2009·Application pending·0 cites
- 1564US2020025775A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2019·Application pending·0 cites
- 1663US2019310266A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2018·Application pending·0 cites
- 1761US10442859B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Oct 15, 2019·0 cites·12 claims
- 1859US2005025763A1Therapeutic use of anti-CS1 antibodiesPROTEIN DESIGN LABS INC·Filed 2004·Application pending·0 cites
- 1956US2013109032A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2011·Application pending·0 cites
- 2056US2017102393A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2016·Application pending·0 cites
- 2153US2022403033A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2022·Application pending·0 cites
- 2250US2016209426A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2015·Application pending·0 cites
- 2344US2021238288A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2437US2014120084A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marna Williams files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →